Hagop Kantarjian: Dasatinib and Venetoclax is safe and effective in newly diagnosed CML in CP

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Dasatinib and Venetoclax is safe and effective in newly diagnosed Chronic Myeloid Leukaemia in CP, but no better than single-agent Dasatinib, longer follow-up needed to evaluate impact on TFR.”

Additional information.
Source: Hagop Kantarjian/X